U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C12H11I3N2O5.C7H17NO5
Molecular Weight 839.1531
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEGLUMINE IOXITHALAMATE

SMILES

CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(C(=O)NCCO)=C(I)C(C(O)=O)=C1I

InChI

InChIKey=IFTFXKNYTWAOGK-WZTVWXICSA-N
InChI=1S/C12H11I3N2O5.C7H17NO5/c1-4(19)17-10-8(14)5(11(20)16-2-3-18)7(13)6(9(10)15)12(21)22;1-8-2-4(10)6(12)7(13)5(11)3-9/h18H,2-3H2,1H3,(H,16,20)(H,17,19)(H,21,22);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

HIDE SMILES / InChI

Description

Ioxitalamic acid is a contrast media, which was used as a meglumine salt under the name Telebrix for intravenous urography; computed tomography; digital angiography; angiocardiography (ventriculography, coronary angiography). The drug is no longer available on the market.

Approval Year

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
TELEBRIX
Diagnostic
TELEBRIX
Diagnostic
TELEBRIX

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
The recommended doses are 1.0 ml/kg (Intravenous urography); 1 and 1.8 ml/kg (computed tomography of brain and computed tomography of the whole body, respectively); 40 ml (ventriculography); 4-8 ml (coronary angiography). The solution for injection contains 350 mg iode/ml.
Route of Administration: Intravenous
In Vitro Use Guide
Ioxitalamic acid was added to human basophils and mast cells isolated from lung, skin, and heart tissue at concentration of 0.1 to 0.5 mol/L (Telebrix preparation). The drug induced histamine release from basophils and histamine and tryptase release from human heart mast cells.